Cutaneous T-cell Lymphoma
Cutaneous T-cell lymphoma is a rare type of cancer that affects T-cells, a kind of white blood cell, primarily involving the skin. It can manifest as patches, plaques, or tumors on the skin.
Cutaneous T-Cell Lymphoma: Mogamulizumab and Skin Radiation Therapy
We are studying a new treatment combining an antibody and skin radiation for patients with stage IB-IIB cutaneous T-cell lymphoma. The goal is to see if this approach improves survival and response rates compared to standard treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Mycosis Fungoides and Sézary Syndrome
Mycosis Fungoides and Sézary Syndrome are two forms of cutaneous T-cell lymphoma, characterized by skin lesions and potential involvement of the blood and lymphatic system. Symptoms may include itchy skin and visible lesions.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have mycosis fungoides at stage IB, IIA, or IIB?
- Have you failed at least one prior treatment for your condition?
- Do you have any significant uncontrolled health issues right now?
- Have you ever been treated with mogamulizumab?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Copenhagen University Hospital
Oncology
Copenhagen, Denmark
Centre Hospitalier Universitaire De Bordeaux
Dermatology
Bordeaux, France
Assistance Publique Hopitaux De Paris
Dermatology
Quinze-Vingts, France
Sponsor: European Organisation For Research And Treatment Of Cancer
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.